PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

被引：13
作者：
Cainzos-Achirica, Miguel [1 ]
Martin, Seth S. [1 ]
Cornell, John E.
Murow, Cynthia D.
Guallar, Eliseo
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 01期
关键词：
HYPERCHOLESTEROLEMIA; LDL;
D O I：
10.7326/M15-0920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [31] PCSK9: an emerging target for treatment of hypercholesterolemia
    Duff, Christopher J.
    Hooper, Nigel M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (02) : 157 - 168
  • [32] Role of PCSK9 inhibitors in the management of dyslipidaemia
    Nair, Tiny
    INDIAN HEART JOURNAL, 2024, 76 : S44 - S50
  • [33] The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia
    White, C. Michael
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (04) : 301 - 308
  • [34] Unexpected roles for PCSK9 in lipid metabolism
    Soutar, Anne K.
    CURRENT OPINION IN LIPIDOLOGY, 2011, 22 (03) : 192 - 196
  • [35] PCSK9 INHIBITORS AS LDL CHOLESTEROL-LOWERING AGENTS: RATIONALE, CONCERNS AND PRELIMINARY OUTCOMES
    Costet, P.
    DRUGS OF THE FUTURE, 2012, 37 (05) : 331 - 341
  • [36] PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub, William S.
    Gidding, Samuel S.
    PHARMACOECONOMICS, 2016, 34 (03) : 217 - 220
  • [37] Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
    Sattar, Naveed
    Preiss, David
    Robinson, Jennifer G.
    Djedjos, C. Stephen
    Elliott, Mary
    Somaratne, Ransi
    Wasserman, Scott M.
    Raal, Frederick J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05) : 403 - 410
  • [38] Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors
    Valero-Masa, Maria Jesus
    Ortiz-Bautista, Carlos David
    Castrodeza, Javier
    Martinez-Selles, Manuel
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (35) : 2797 - 2800
  • [39] LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    Sabatel-Perez, F.
    Garcia-Ropero, A.
    Santos-Gallego, G.
    Zafar, M. Urooj
    Badimon, J. J.
    DRUGS OF TODAY, 2019, 55 (05) : 329 - 344
  • [40] A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
    Chen, Bo
    Shi, Xin
    Cui, Yanping
    Hou, Aiping
    Zhao, Pengjun
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (20) : 1790 - 1817
12345